Eggermont AM - Search Results

1

Update: current management issues in malignant melanoma.

Queirolo P, Acquati M, Kirkwood JM, Eggermont AM, Rocca A, Testori A. Queirolo P, et al. Among authors: eggermont am. Melanoma Res. 2005 Oct;15(5):319-24. doi: 10.1097/00008390-200510000-00001. Melanoma Res. 2005. PMID: 16179860 Review.

2

The role of regional isolated perfusion in the eradication of melanoma micrometastases in the inguinal nodes: a comparison between an iliac and femoral perfusion procedure.

Klaase JM, Kroon BB, van Geel AN, Eggermont AM, Franklin HR, van Dongen JA. Klaase JM, et al. Among authors: eggermont am. Melanoma Res. 1992 Dec;2(5-6):407-10. doi: 10.1097/00008390-199212000-00016. Melanoma Res. 1992. PMID: 1292788 Clinical Trial.

3

Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs?

Klaase JM, Kroon BB, van Geel AN, Eggermont AM, Franklin HR, van Dongen JA. Klaase JM, et al. Among authors: eggermont am. Melanoma Res. 1994 Mar;4 Suppl 1:13-6. Melanoma Res. 1994. PMID: 8038589 Clinical Trial.

4

Results of regional isolated perfusion for locally inoperable melanoma of the limbs.

Kapteijn BA, Klaase JM, van Geel AN, Eggermont AM, Kroon BB. Kapteijn BA, et al. Among authors: eggermont am. Melanoma Res. 1994 Apr;4(2):135-8. doi: 10.1097/00008390-199404000-00008. Melanoma Res. 1994. PMID: 8069099 Clinical Trial.

5

The current EORTC Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: prognosis versus efficacy, toxicity and costs.

Eggermont AM. Eggermont AM. Melanoma Res. 1997 Aug;7 Suppl 2:S127-31. Melanoma Res. 1997. PMID: 9578428 Review.

6

Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.

Eggermont AM. Eggermont AM. Recent Results Cancer Res. 2000;157:178-89. doi: 10.1007/978-3-642-57151-0_15. Recent Results Cancer Res. 2000. PMID: 10857171 Review.

7

The AJCC staging proposal for cutaneous melanoma: comments by the EORTC Melanoma Group.

Ruiter DJ, Testori A, Eggermont AM, Punt CJ. Ruiter DJ, et al. Among authors: eggermont am. Ann Oncol. 2001 Jan;12(1):9-11. doi: 10.1023/a:1008303314855. Ann Oncol. 2001. PMID: 11249056 Free article. No abstract available.

8

The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer.

Eggermont AM, Keilholz U, Testori A, Cook M, Lienard D, Ruiter DJ. Eggermont AM, et al. Ann Surg Oncol. 2001 Oct;8(9 Suppl):38S-40S. Ann Surg Oncol. 2001. PMID: 11599896 Clinical Trial.

9

The role interferon-alpha in malignant melanoma remains to be defined.

Eggermont AM. Eggermont AM. Eur J Cancer. 2001 Nov;37(17):2147-53. doi: 10.1016/s0959-8049(01)00272-6. Eur J Cancer. 2001. PMID: 11677100 Review.

10

European approach to the treatment of malignant melanoma.

Eggermont AM. Eggermont AM. Curr Opin Oncol. 2002 Mar;14(2):205-11. doi: 10.1097/00001622-200203000-00011. Curr Opin Oncol. 2002. PMID: 11880712 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

660 results

Search Page

Filters